NOVO — Februar 2025
-
Within R&D, CagriSema demonstrated superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial, where people treated with CagriSema achieved a superior weight loss of 22.7%. Further, semaglutide 7.2 mg achieved 20.7% weight loss in the STEP UP obesity trial. Lastly, a phase 1b/2a with injectable amycretin in people with overweight or obesity was successfully completed.
-
In December 2024, Novo Nordisk announced that the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings was completed.
For the 2025 outlook, sales growth is expected to be 16-24% at CER, and operating profit growth is expected to be 19-27% at CER. Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively. -
-
Novo Nordisk: Stærk afslutning på et udfordrende 2024. 2025 tegner godt https://proinvestor.com/boards/124565
-
Novos 2025-prognose favner fint analytikernes estimater - skruer heftigt op for investeringerne https://proinvestor.com/investornyt/1274010/novos-2025-prognose-favner-fint-analytikernes-estimater-skruer-heftigt-op-for-investeringerne
-
Novos salg af Ozempic i fjerde kvartal slår forventningerne https://proinvestor.com/investornyt/1274012/novos-salg-af-ozempic-i-fjerde-kvartal-slar-forventningerne
-
Novos prognose for 2025 bør skabe lettelse vurderer Sydbank https://proinvestor.com/investornyt/1274027/novos-prognose-for-2025-bor-skabe-lettelse-vurderer-sydbank
-
Novo Nordisk vil søge om godkendelse af Cagrisema i første kvartal af 2026 https://proinvestor.com/investornyt/1274025/novo-nordisk-vil-soge-om-godkendelse-af-cagrisema-i-forste-kvartal-af-2026
-
Novos topchef om Wegovy-salg i USA: Prognosen forudsætter væsentlig stigning https://proinvestor.com/investornyt/1274049/novos-topchef-om-wegovy-salg-i-usa-prognosen-forudsaetter-vaesentlig-stigning
-
Fra MW "Lars Fruergaard Jørgensen om desing.
Han peger på, at det på forhånd stod klart, at behandlingen med et potent lægemiddel som Cagrisema ville give anledning til et endda meget væsentlig vægttab for mange af patienterne over meget kort tid. Og netop derfor blev studiet designet, så studiets deltagere selv havde mulighed at afgøre deres dosis.- Havde vi ikke givet mulighed for det, så løber man risikoen for, at patienterne var droppet ud af studiet, ikke på grund af klassiske grunde
-
som bivirkninger, men fordi de føler, at de har tabt den vægt, de ønsker. Og hvis det sker, så kan det få indflydelse på hele studiets integritet og muligheden for at få midlet godkendt, da der skal være et vist antal patienter i studiet, som fortsætter i behandling, siger Lars Fruergaard Jørgensen."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind